Previous 10 | Next 10 |
ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference ESSA Pharma to Present at the Bloom Burton & Co. Healthcare Investor Conference PR Newswire HOUSTON , Texas and VANCOUVER, Canada , April 14, 2021 /PRNewswire/ - ...
ESSA Pharma Presents Preclinical Data Supporting the Therapeutic Potential of EPI-7386 at the 2021 American Association of Cancer Research (AACR) Annual Meeting PR Newswire HOUSTON , Texas and VANCOUVER, Canada, April 10, 2021 /PRNewswire/ -- ESSA ...
ESSA Announces Change to its Board of Directors PR Newswire HOUSTON , Texas and VANCOUVER, BC , March 26, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel t...
The following slide deck was published by ESSA Pharma Inc. in conjunction with this event. For further details see: ESSA Pharma (ESSA) Investor Presentation - Slideshow
ESSA Pharma Announces Exercise of Option in Connection with Recently Completed $130 Million Financing PR Newswire VANCOUVER, BC and HOUSTON , March 4, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharm...
BOSTON, MA / ACCESSWIRE / March 2, 2021 / Block & Leviton LLP ( www.blockleviton.com ), a national securities litigation firm, announces that a lawsuit for violation of the federal securities laws has been filed against Ebix, Inc. (NASDAQ:EBIX) and certain of its executives. The deadline...
ESSA Pharma to Present at Upcoming March Investor Conferences PR Newswire HOUSTON, Texas and VANCOUVER, Canada, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on d...
ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer Canada NewsWire HOUSTON, Texas and VANCOUVER, Canada , Feb. 25, 2021 /CNW/ - ...
ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock Canada NewsWire VANCOUVER, BC and HOUSTON , Feb. 22, 2021 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused o...
ESSA Pharma (EPIX) has priced its public offering of ~4.8M common shares at $27.00/share, for gross proceeds of ~$130.4M.Underwriters' over-allotment is an additional ~724.6K shares.Net proceeds will be used for pre-clinical and clinical activities, manufacturing and controls, R&D, workin...
News, Short Squeeze, Breakout and More Instantly...
ESSA Pharma to Present at the JonesHealthcare Seaside Summit Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 8, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on de...
ESSA Pharma to Present at the Jefferies Global Healthcare Conference Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 30, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focus...